AlgaeBio Announces Omega-3 Distribution Contract with Global Health Trax

Vancouver, British Columbia--(October 13, 2011) - Algae Biosciences Corporation (TSXV: ABV) is pleased to confirm that it has a comprehensive purchase and distribution contract in place with Global Health Trax ("GHT") regarding AlgaeBio's algae-based, omega-3 products.

The contract gives Global Health Trax, based in Vista, Calif., exclusive rights to purchase and distribute AlgaeBio's ultra-pure omega-3 products destined for the nutraceutical, food additive, and animal feed markets.

"GHT has developed global channels of distribution," notes AlgaeBio Chairman Robert J. Thompson. "This contract will help to establish AlgaeBio's worldwide reach with a wide variety of core and supplemental products."

AlgaeBio, a Canadian public biotechnology company, announced in mid-August a $5-million, first-phase expansion of its production facilities near Holbrook, Ariz. The first order of business will be ramping up to large-scale commercial production of ultra-pure, algae-based omega-3 fatty acid oils by early 2012.

AlgaeBio's omega-3 products contain both EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), essential long-chain fatty acids that provide a wide range of health benefits. The vast majority of competing products on the market contain one or the other, usually DHA, and many are purity challenged.

Global Health Trax, established in 1996, is an industry leader in nutraceutical formulation and distribution on a worldwide basis. The company's acknowledged expertise is in the maintenance of healthy digestive processes; GHT markets and sells a distinctive line of health products, including probiotics, enzymes, antioxidants, and other important nutraceuticals, that focus on the digestive system.

-30-

ABOUT ALGAE BIOSCIENCES CORPORATION: AlgaeBio is a Canadian biotechnology company that researches, develops, and manufactures ultra-pure products from micro and macro algae such as nutraceuticals, food additives, and pharmaceuticals. With access to near-perfect algae growing conditions, exclusive aquaculture access to a pristine brine water supply, and advanced proprietary technology, AlgaeBio produces superior human and animal consumable products, as well as offering advanced algae-based products and technologies for distribution into the agribusiness, biofuel, and aquaculture markets. AlgaeBio owns and operates large-scale production facilities near Holbrook, Ariz., and is listed on the TSX Venture Exchange (TSX.V:ABV).

For more information:

Robert J. Thompson
Chairman of the Board
Algae Biosciences Corporation
Phone: 602.909.9728
E-mail: r.thompson@algaebio.com

Cautionary Statements

This news release contains "forward-looking statements" within the meaning of applicable securities laws, including statements relating to the expenditure of funds acquired by the Corporation in connection with the Offering. Although the Corporation believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to the Corporation. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements, including whether or not the Agent's Option is ultimately exercised. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this press release are made as of the date of this release and, except as required by applicable law, the Corporation does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The Corporation undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Corporation or its financial or operating results or (as applicable), their securities.

The Common Shares have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this release.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS.